ArticleOncotarget2016

Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b.

Elisabetta Vergani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.